Literature DB >> 9435989

Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias.

D J Clarke1, N Moghrabi, G Monaghan, A Cassidy, M Boxer, R Hume, B Burchell.   

Abstract

Congenital familial non-haemolytic hyperbilirubinaemias are potentially lethal syndromes caused by genetic lesions that reduce or abolish hepatic bilirubin UDP-glucuronosyltransferase activity. Here we describe genetic defects that occur in the UGT1 gene complex that cause three non-haemolytic unconjugated hyperbilirubinaemia syndromes. The most severe syndrome, termed Crigler-Najjar syndrome type I, is mainly associated with mutations in exons 2 to 5 that affect all UGT1 enzymes and many of the mutations result in termination codons and frameshifts. Crigler-Najjar type II syndrome which is treatable with phenobarbital therapy is associated with less dramatic missense mutations or heterozygous expression of mutant and normal alleles. Gilbert's syndrome, the most prevalent (2-19% in population studies) and mildest of the three syndromes is principally caused by a TA insertion at the TATA promoter region upstream of the UGT1A1 exon. Current methods used for the diagnosis and treatment of these diseases are discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9435989     DOI: 10.1016/s0009-8981(97)00167-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  20 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Gilbert's syndrome: High frequency of the (TA)7 TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene.

Authors:  Shabana Farheen; Sanghamitra Sengupta; Amal Santra; Suparna Pal; Gopal Krishna Dhali; Meenakshi Chakravorty; Partha P Majumder; Abhijit Chowdhury
Journal:  World J Gastroenterol       Date:  2006-04-14       Impact factor: 5.742

3.  The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients.

Authors:  Suad AlFadhli; Hassan Al-Jafer; Mays Hadi; Mashael Al-Mutairi; Rasheeba Nizam
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

4.  Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease.

Authors:  Arno Lingenhel; Barbara Kollerits; Johannes P Schwaiger; Steven C Hunt; Richard Gress; Paul N Hopkins; Veit Schoenborn; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-08-26       Impact factor: 4.032

5.  North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.

Authors:  Robert R McWilliams; Nathan R Foster; Michelle R Mahoney; Thomas C Smyrk; Joseph A Murray; Matthew M Ames; L Elise Horvath; Daniel J Schneider; Timothy J Hobday; Aminah Jatoi; Jeffrey P Meyers; Matthew P Goetz
Journal:  Cancer       Date:  2017-05-10       Impact factor: 6.860

6.  Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα.

Authors:  Terry D Hinds; Peter A Hosick; Shujuan Chen; Robert H Tukey; Michael W Hankins; Andrea Nestor-Kalinoski; David E Stec
Journal:  Am J Physiol Endocrinol Metab       Date:  2017-01-17       Impact factor: 4.310

7.  Jaundice with hypertrophic pyloric stenosis as an early manifestation of Gilbert syndrome.

Authors:  P Trioche; J Chalas; J Francoual; L Capel; A Lindenbaum; M Odièvre; P Labrune
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

8.  Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?

Authors:  Terry D Hinds; Samuel O Adeosun; Abdulhadi A Alamodi; David E Stec
Journal:  Med Hypotheses       Date:  2016-08-31       Impact factor: 1.538

Review 9.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Inherited disorders of bilirubin clearance.

Authors:  Naureen Memon; Barry I Weinberger; Thomas Hegyi; Lauren M Aleksunes
Journal:  Pediatr Res       Date:  2015-11-23       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.